Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and ...

The findings highlight the need for public-health strategies aimed at mitigating dementia risk and promoting healthy aging across diverse populations, researchers said. “I think ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a ...

Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades,” said ...

When people think of Alzheimer's, memory loss immediately comes to mind. However, the early symptoms of Alzheimer's extend ...

Experts say there are ways to reduce our risk of dementia, including diet and exercise, protecting against hearing loss, and ...

Having depression is known to increase a person's risk of developing dementia, but depression is also an early indicator of ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

Researchers have developed a flexible, biodegradable electrode capable of stimulating neural precursor cells (NPCs) in the ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.